The current knowledge concerning solid cancer and therapy DOI
Masoud Najafi, Jamal Majidpoor, Heidar Toolee

et al.

Journal of Biochemical and Molecular Toxicology, Journal Year: 2021, Volume and Issue: 35(11)

Published: Aug. 31, 2021

Abstract Solid cancers comprise a large number of new cases and deaths from cancer each year globally. There are strategies for addressing tumors raised solid organs including surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, combinational stem cell extracellular vesicle (EV) therapy. Surgery, chemotherapy the dominant cures, but not always effective, in which even localized tumor there is possibility relapse after surgical resection. Over half patients will receive radiotherapy as part their therapeutic schedule. Radiotherapy can cause an abscopal response boosting activity immune system outside local field radiation, it may also unwanted bystander effect, predisposing nonradiated cells into carcinogenesis. In context checkpoint inhibition known standard‐of‐care, major concern regard with cold that show low responses to such Stem‐cell therapy be used send prodrugs toward area; this strategy, however, has its own predicaments, attraction other sites healthy tissues instability. A substitute quite novel strategy use EVs, by virtue stability potential cross biological barriers long‐term storage contents. Combination current focus. Despite advances field, still unmet concerns area effective raising challenges opportunities future investigations.

Language: Английский

The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications DOI Creative Commons
Hongmei Zheng, Yuting Zhan, Sile Liu

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2018, Volume and Issue: 37(1)

Published: Sept. 14, 2018

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of cases, and it is one the leading causes death in both men women worldwide due to diagnosis advanced stage, rapid metastasis, recurrence. At present, precision molecular targeted therapeutics directed toward NSCLC driven genes has made great progress significantly improved overall survival patients with NSCLC, but can easily lead acquired drug resistance. New methods are needed develop real-time monitoring efficacy resistance, such as new markers more effective early detection prediction prognosis. Exosomes nano-sized extracellular vesicles, containing proteins, nucleic acids lipids, which secreted by various cells, they play an important role development controlling a wide range pathways. Tumor-derived exosomes significance guiding therapy themselves be target treatment. In this review, we describe potential roles tumor-derived their clinical NSCLC.

Language: Английский

Citations

126
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial DOI Creative Commons
James Chih‐Hsin Yang, D. Ross Camidge, Cheng‐Ta Yang

et al.

Journal of Thoracic Oncology, Journal Year: 2020, Volume and Issue: 15(12), P. 1907 - 1918

Published: Sept. 9, 2020

Language: Английский

Citations

125
New insights into small‐cell lung cancer development and therapy DOI Creative Commons
Yuwen Wang, Songyun Zou, Zhuyun Zhao

et al.

Cell Biology International, Journal Year: 2020, Volume and Issue: 44(8), P. 1564 - 1576

Published: April 13, 2020

Small-cell lung cancer (SCLC) accounts for approximately 15% of cases; however, it is characterized by easy relapse and low survival rate, leading to one the most intractable diseases in clinical practice. Despite decades basic research, little progress has been made management SCLC. The current standard first-line regimens SCLC still remain be cisplatin or carboplatin combined with etoposide, adverse events chemotherapy are no means negligible. Besides, immunotherapy on an early stage novel studies urgently needed. In this review, we describe development therapy, aiming at providing useful advices research strategy.

Language: Английский

Citations

108
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function DOI

Lingyue Gao,

Zhuo‐Xun Wu,

Yehuda G. Assaraf

et al.

Drug Resistance Updates, Journal Year: 2021, Volume and Issue: 57, P. 100770 - 100770

Published: June 18, 2021

Language: Английский

Citations

96
The current knowledge concerning solid cancer and therapy DOI
Masoud Najafi, Jamal Majidpoor, Heidar Toolee

et al.

Journal of Biochemical and Molecular Toxicology, Journal Year: 2021, Volume and Issue: 35(11)

Published: Aug. 31, 2021

Abstract Solid cancers comprise a large number of new cases and deaths from cancer each year globally. There are strategies for addressing tumors raised solid organs including surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, combinational stem cell extracellular vesicle (EV) therapy. Surgery, chemotherapy the dominant cures, but not always effective, in which even localized tumor there is possibility relapse after surgical resection. Over half patients will receive radiotherapy as part their therapeutic schedule. Radiotherapy can cause an abscopal response boosting activity immune system outside local field radiation, it may also unwanted bystander effect, predisposing nonradiated cells into carcinogenesis. In context checkpoint inhibition known standard‐of‐care, major concern regard with cold that show low responses to such Stem‐cell therapy be used send prodrugs toward area; this strategy, however, has its own predicaments, attraction other sites healthy tissues instability. A substitute quite novel strategy use EVs, by virtue stability potential cross biological barriers long‐term storage contents. Combination current focus. Despite advances field, still unmet concerns area effective raising challenges opportunities future investigations.

Language: Английский

Citations

93